metronidazole has been researched along with Gastroduodenal Ulcer in 255 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inpatients with peptic ulcer complications who were not able to take oral medicine were randomly assigned to three groups: triple therapy (esomeprazole, levofloxacin, metronidazole) and dual therapy (esomeprazole, levofloxacin/metronidazole) for 7 days." | 9.69 | Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study. ( Chen, J; Gui, Q; Liang, X; Lu, H; Su, W; Yu, D; Zhang, W; Zhu, C, 2023) |
| "Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H." | 9.17 | Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Saif, R; Shah, A; Shoukat, A; Sodhi, JS; Teli, F; Yattoo, GN; Zargar, SA, 2013) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 9.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| " pylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (OAM group, n = 45)." | 9.11 | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. ( Cao, DZ; Fu, XL; Hu, JM; Ou, XL; Su, H; Sun, WH; Sun, YL; Yu, Q; Yu, T; Zhu, F, 2005) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 9.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 9.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| "In this prospective controlled study conducted in a single center, 78 symptomatic peptic ulcer patients were treated for 4 wk with omeprazole 40 mg o." | 9.08 | Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? ( Anania, MC; Annibale, B; D'Ambra, G; Delle Fave, G; Iannoni, C; Luzzi, I; Marcheggiano, A; Marignani, M; Paoletti, M, 1997) |
| "A total of 152 patients with recurrent peptic ulcer disease were treated with bismuth subnitrate, oxytetracycline and metronidazole." | 9.07 | Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. ( Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I, 1994) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 9.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 7.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "Inpatients with peptic ulcer complications who were not able to take oral medicine were randomly assigned to three groups: triple therapy (esomeprazole, levofloxacin, metronidazole) and dual therapy (esomeprazole, levofloxacin/metronidazole) for 7 days." | 5.69 | Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study. ( Chen, J; Gui, Q; Liang, X; Lu, H; Su, W; Yu, D; Zhang, W; Zhu, C, 2023) |
| "Pre-treatment metronidazole susceptible H pylori were significantly more likely to respond to the triple therapy used than those with the metronidazole resistant ones (14 of 15 v five of 10) (p = 0." | 5.29 | Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. ( Ching, CK; Lai, CL; Lai, KC; Lam, SK; Leung, KP; Wong, BC; Yung, RW, 1996) |
| "Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H." | 5.17 | Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Saif, R; Shah, A; Shoukat, A; Sodhi, JS; Teli, F; Yattoo, GN; Zargar, SA, 2013) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 5.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| " pylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (OAM group, n = 45)." | 5.11 | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. ( Cao, DZ; Fu, XL; Hu, JM; Ou, XL; Su, H; Sun, WH; Sun, YL; Yu, Q; Yu, T; Zhu, F, 2005) |
| "The purpose of this study was to compare the efficacy of tinidazole- versus clarithromycin-based triple regimens for eradication of Helicobacter pylori in North Indian patients of peptic ulcer disease, and to correlate the outcome with in vitro antibiotic susceptibility." | 5.11 | Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. ( Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP, 2004) |
| " pylori positive peptic ulcer disease or functional dyspepsia were treated with two-day quadruple therapy (lansoprazole 30 mg twice daily, and colloidal bismuth subcitrate 120 mg, tetracycline 250 mg and metronidazole 250 mg, all eight times a day)." | 5.11 | The influence of pretreatment on cure rates of Helicobacter pylori eradication. ( de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ, 2004) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 5.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| "Clinical efficiency and safety of Epigam containing antibodies to histamine in ultralow doses were studied during the therapy of patients with exacerbation of peptic ulcer disease of the stomach and duodenum associated with Helicobacter pylori infection." | 5.10 | Clinical efficiency of Epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. ( Bakumov, PA; Dugina, YL; Epstein, OI; Sergeeva, SA; Shchepotkin, IV, 2003) |
| "We conducted a prospective, uncontrolled study of a consecutive series of 21 peptic ulcer patients with failure of 1-week lansoprazole, amoxicillin, and clarithromycin." | 5.09 | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. ( Ducóns, JA; Ferrero, M; García Cabezudo, J; Gomollón, F; Guirao, R; Montoro, M; Simón, MA, 1999) |
| "Ninety patients with established peptic ulcer and NUD (with previously proven ulcer) were randomly assigned to receive either bismuth-subcitrate, amoxycillin and metrnidazole (BAM) or lansoprasole, clarithromycine and metronidazole (LCM) for 7 days." | 5.09 | The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. ( Avidan, B; Bar-Meir, S; Keller, N; Melzer, E, 2001) |
| "A total of 122 consecutive patients with peptic ulcer and Helicobacter pylori infection were treated with omeprazole 20 mg b." | 5.09 | Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment. ( Brullet, E; Calvet, X; Campo, R; Garcia, N; Gené, E; Sanfeliu, I, 2001) |
| "Lansoprazole-based quadruple therapy achieves a very high cure rate in an unselected population of either peptic ulcer patients or those with H." | 5.08 | Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. ( Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB, 1998) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 5.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| " pylori-positive peptic ulcer received omeprazole 20 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 500 mg twice daily for seven days." | 5.08 | One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? ( Bhutta, AS; Bindel, H; Cunnane, K; Loane, J; O'Connor, HJ, 1997) |
| " pylori infection and peptic ulcer disease (n = 64) or functional dyspepsia (n = 16), with similar demographic and clinical characteristics, were treated for 1 week with either omeprazole 20 mg once in the morning and clarithromycin 250 mg and metronidazole 400 mg twice daily (OCM; n = 40) or with omeprazole 20 mg once in the morning and clarithromycin 250 mg and tetracycline 500 mg twice daily (OCT; n = 40)." | 5.08 | One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Rühl, GH; Sollböhmer, M; Stolte, M; Tillenburg, B, 1995) |
| "Eradication of Helicobacter pylori from the stomach by triple therapy with bismuth, tetracycline, and metronidazole cures peptic ulcer disease." | 5.08 | Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. ( de Boer, W; Driessen, W; Jansz, A; Tytgat, G, 1995) |
| "Eighty-two patients with severe peptic ulcer disease and concurrent Helicobacter pylori infection were treated with a two week regimen of omeprazole (40 mg once daily), amoxycillin (750 mg t." | 5.08 | Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori. ( Jönsson, KA; Sörberg, M; Ström, M, 1997) |
| "Patients with active HP infection and peptic ulcer, a history of peptic ulcer, or nonulcer dyspepsia were randomized to either lansoprazole 30 mg b." | 5.08 | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. ( Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM, 1997) |
| "In this prospective controlled study conducted in a single center, 78 symptomatic peptic ulcer patients were treated for 4 wk with omeprazole 40 mg o." | 5.08 | Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? ( Anania, MC; Annibale, B; D'Ambra, G; Delle Fave, G; Iannoni, C; Luzzi, I; Marcheggiano, A; Marignani, M; Paoletti, M, 1997) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 5.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| "A total of 152 patients with recurrent peptic ulcer disease were treated with bismuth subnitrate, oxytetracycline and metronidazole." | 5.07 | Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. ( Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I, 1994) |
| "Thirty-one patients with major upper gastrointestinal bleeding from peptic ulcer were studied; 17 received triple therapy and 14 ranitidine alone." | 5.07 | Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. ( Graham, DY; Hepps, KS; Lew, GM; Ramirez, FC; Saeed, ZA, 1993) |
| " pylori eradication is achieved; (5) the eradication rates seem to be higher in peptic ulcer than in nonulcer dyspepsia; (6) in areas where the prevalence of metronidazole resistance is high, triple therapy including a PPI, clarithromycin, and amoxicillin is the best option, and (7) quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is the recommended second-line therapy after PPI-clarithromycin-amoxicillin failure, although replacing the PPI and the bismuth compound by ranitidine bismuth citrate achieves also good results." | 4.81 | Helicobacter pylori therapy: first-line options and rescue regimen. ( Gisbert, JP; Pajares, JM, 2001) |
| " Metronidazole resistance in peptic ulcer patients was significantly higher." | 3.83 | A high-throughput multiplex genetic detection system for Helicobacter pylori identification, virulence and resistance analysis. ( Bian, H; Fang, Y; Hu, B; Kong, M; Miao, Y; Olszewski, MA; Wang, S; Wu, Y; Xu, L; Yang, C; Zhang, Y; Zhao, F; Zhao, H, 2016) |
| " pylori culture positive dyspeptic patients (64 patients with peptic ulcer, PU) completed a 2-week treatment with omeprazole, amoxicillin and metronidazole and underwent endoscopy again 6-8 weeks after the end of therapy." | 3.78 | Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection. ( Figura, N; Giordano, N; Langone, F; Moretti, E; Vaglio, L; Vernillo, R; Vindigni, C, 2012) |
| " pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole." | 3.76 | Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. ( Bielicki, D; Droździk, M; Gawrońska-Szklarz, B; Kurzawski, M; Marlicz, W; Siuda, A, 2010) |
| "Patients with peptic ulcer who failed with first-line triple eradication therapy containing clarithromycin received quadruple therapy with omeprazole (20 mg, twice daily), amoxicillin (750 mg, twice daily), metronidazole (500 mg, twice daily) and ecabet sodium (1000 mg, twice daily) for 14 days." | 3.76 | Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). ( Ae, T; Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Tanabe, S, 2010) |
| " pylori eradication in peptic ulcer patients treated with pantoprazole." | 3.73 | Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. ( Droździk, M; Gawrońska-Szklarz, B; Kurzawski, M; Siuda, A; Starzyńska, T; Wrześniewska, J, 2006) |
| " pylori isolates from patients with peptic ulcer disease reporting for clinical management to the Post Graduate Institute of Medical Education and Research, Chandigarh; All India Institute of Medical Sciences, New Delhi; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow; Deccan College of Medical Sciences and Allied Hospitals, Hyderabad; and hospitals in Chennai in collaboration with the Dr ALM Post Graduate Institute of Basic Medical Sciences were analyzed for their levels of antibiotic susceptibility to metronidazole, clarithromycin, amoxycillin, ciprofloxacin and tetracycline." | 3.72 | Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. ( Ayyagari, A; Bhasin, D; Das, BK; Dharmalingam, S; Habibullah, CM; Khan, AA; Naik, SR; Rajasambandam, P; Ramathilagam, B; Rao, UA; Ray, P; Sharma, MP; Thyagarajan, SP, 2003) |
| "One hundred eight patients with cultured H pylori-positive gastritis or peptic ulcer were treated with three regimens: quadruple treatment without proton pump inhibitors (n = 25), dual treatment with omeprazole and amoxicillin (INN, amoxicilline) (n = 26), and triple treatment with omeprazole, amoxicillin, and clarithromycin (n = 57)." | 3.70 | CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. ( Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y, 1999) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 3.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "The prevalence of metronidazole and clarithromycin resistance of Helicobacter pylori strains under different growth conditions (microaerophilic or anaerobic preincubation) was tested in 56 patients suffering from gastritis and peptic ulcer." | 3.70 | Metronidazole and clarithromycin susceptibility and the subtypes of vacA of Helicobacter pylori isolates in Estonia. ( Kasenõmm, P; Kolk, H; Lõivukene, K; Maaroos, HI; Mikelsaar, M; Ustav, M, 2000) |
| "Fifty-two patients with peptic ulcer disease and antral biopsies containing Helicobacter pylori sensitive to metronidazole were given a 7-day course of treatment: omeprazole 20 mg b." | 3.69 | A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. ( Scott, BB; Vautier, G, 1997) |
| " pylori-positive patients with recurrent peptic ulcer diseases, 29 of whom were given triple therapy (amoxycillin and metronidazole for 1 week and plaunotol for 4 weeks)." | 3.69 | Evaluation of a new bismuth-free triple therapy in nude mice and humans. ( Karita, M; Nakazawa, T; Okita, K; Sugiyama, T; Tsuda, M, 1995) |
| " pylori infection and peptic ulcer disease or functional dyspepsia were treated with either omeprazole 20 mg b." | 3.69 | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1996) |
| " Thirty-two consecutive patients (suffering from either peptic ulcer or nonulcer dyspepsia) with Helicobacter pylori infection received omeprazole (40 mg) + bismuth subcitrate (240 mg x 4) + amoxicillin suspension (2000 mg x 4) + metronidazole (500 mg x 4), for only one day." | 3.68 | One-day therapy for treatment of Helicobacter pylori infection. ( Barbara, L; Biasco, G; Corinaldesi, R; Gasperoni, S; Paparo, GF; Ricci-Maccarini, M; Stanghellini, V; Tucci, A; Varoli, O, 1993) |
| " The incidence of adverse events with the use of triple, four-component and hybrid ET regimens was 15; 18." | 2.87 | Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. ( Andreev, DN; Dicheva, DT; Maiev, IV; Partzvania-Vinogradova, EV; Yurenev, GL, 2018) |
| "Levodopa was prescribed for groups 1 and 3." | 2.72 | Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial. ( Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR, 2006) |
| "Peptic ulcer was found in 6." | 2.71 | Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. ( Färkkilä, M; Sarna, S; Sipponen, P; Valtonen, V, 2004) |
| "Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category." | 2.71 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. ( Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Pretreatment with omeprazole did not reduce the cure rate for this new quadruple therapy." | 2.69 | A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. ( Maeda, K; Nishimura, H; Oda, K; Ohkuma, K; Okabe, N; Okada, M; Oki, K; Seo, M; Shirotani, T, 1998) |
| "pylori recurrence rate." | 2.69 | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. ( Iijima, K; Kato, K; Ohara, S; Sekine, H, 1999) |
| " Pre-treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens." | 2.69 | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. ( Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M, 1999) |
| " The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ)." | 2.69 | Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. ( Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J, 1999) |
| "Lansoprazole has superior anti-Helicobacter activity in vitro and possibly also in vivo; therefore we investigated quadruple therapy with lansoprazole." | 2.68 | Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. ( de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ, 1996) |
| " pylori than ranitidine when given with amoxicillin plus metronidazole for the treatment of duodenal ulcer, as both early reinfection and ulcer recurrence are diminished." | 2.68 | Ranitidine versus colloidal bismuth subcitrate in combination with amoxicillin and metronidazole for eradicating Helicobacter pylori in patients with duodenal ulcer. ( Blanco, M; Carpintero, P; Pajares, JM, 1997) |
| "Some recent studies have reported high recurrence rates after apparent cure." | 2.68 | Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. ( De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY, 1996) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| "Most gastroduodenal ulcers are due to HP infection." | 2.52 | [What is new in treating Helicobacter pylori infection?]. ( Fischbach, W; Glocker, E; Malfertheiner, P; Scherübl, H, 2015) |
| "All patients with peptic ulcer disease, gastric cancer, and MALT lymphoma should be tested for Hp." | 2.47 | Diagnosis and treatment of Helicobacter pylori infection. ( Bytzer, P; Dahlerup, JF; Eriksen, JR; Jarbøl, DE; Rosenstock, S; Wildt, S, 2011) |
| "Peptic ulcer is now recognized as a chronic gastric infectious disease." | 2.40 | [Helicobacter pylori infection and ulcer]. ( Blum, AL; Malfertheiner, P, 1998) |
| "Eradication rate of Helicobacter pylori in dual therapy (omeprazole/amoxicillin) are reported in the range of 28-91%, side effect such as loose stool and skin reaction are reported 3." | 2.40 | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. ( Iwasaki, A, 1999) |
| "pylori infection decreases recurrence rates and facilitates healing, antibiotic therapy is indicated for all H." | 2.39 | Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. ( Soll, AH, 1996) |
| "14C-urea breath test was the "gold standard" and the specificity of the biopsy urease test in diagnosing H." | 2.39 | Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. ( Bergseth, M; Berstad, A; Berstad, K; Hundal, O; Olafsson, S; Tefera, S; Wilhelmsen, I, 1996) |
| "pylori eradication is early gastric cancer in addition to the previous indications of peptic ulcer including scar and Marginal zone B cell lymphoma (MALT type)." | 1.35 | [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. ( Choe, YH; Chung, IS; Kim, HS; Kim, JI; Kim, JJ; Kim, N, 2009) |
| "Chronic urticaria is a persistent urticaria lasting longer than 6 weeks, affecting 20% of the general population." | 1.35 | Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies. ( Abdou, AG; Elnaidany, NF; Elshayeb, EI; Farag, AG, 2009) |
| "The influence of synthetic drugs prescribed for peptic ulcer on the pharmacokinetic fate of glycyrrhizin (GL) from Shaoyao-Gancao-tang (SGT, a traditional Chinese formulation, Shakuyaku-Kanzo-to in Japanese) was investigated in rats." | 1.31 | The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang. ( Akao, T; He, JX; Nishino, T; Tani, T, 2001) |
| "pylori induces de novo GERD symptoms in ulcer patients." | 1.31 | Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. ( Dickson, A; El-Nujumi, A; El-Omar, E; Kelman, A; McColl, KE, 2000) |
| "Metronidazole is an important component in most eradication regimens." | 1.31 | Metronidazole-resistant Helicobacter pylori in an urban Asian population. ( Fock, KM; Khor, CJ; Ng, TM; Tan, AL; Teo, EK, 2000) |
| "Clarithromycin resistance was more common in older patients (P<0." | 1.31 | Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period. ( Ducóns, JA; Ferrero, M; Gomollón, F; Santolaria, S; Sicilia, B; Sierra, E, 2000) |
| "1 year after drug therapy the recurrence of CDU is revealed in 16." | 1.31 | [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer]. ( Fedorov, AV; Sazhin, VP, 2001) |
| "In Bangladesh, late recrudescence of H." | 1.31 | Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. ( Ahmad, MM; Arefin, MS; Bardhan, P; Bauerfeind, P; Beglinger, C; Glatz-Krieger, K; Gyr, N; Hasan, M; Hildebrand, P; Khan, AK; Parvin, S; Rahman, A; Rossi, L; Terracciano, L, 2001) |
| "Therefore, the recurrence rate of H." | 1.31 | Six-year follow-up after successful triple therapy for Helicobacter pylori infection in patients with peptic ulcer disease. ( Kleibeuker, JH; Thijs, JC; van der Wouden, EJ; van Zwet, AA, 2001) |
| "Metronidazole resistance was found in 6." | 1.30 | Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases. ( Chang, YS; Cheng, KS; Lin, CW; Wu, SC, 1998) |
| " Discouraging the use of over-the-counter H2 antagonists, ruling out long-term use of nonsteroidal anti-inflammatory drugs before selecting the treatment regimen, and considering expected treatment compliance are important aspects of PUD management that emerged from this case." | 1.30 | Understanding peptic ulcer disease pharmacotherapeutics. ( Navuluri, R; Yue, S, 1999) |
| "One hundred and thirty patients with proven H pylori infection (by at least two tests) were treated with low dose triple therapy (DeNol 1 qid, tetracycline 250 mg qid and metronidazole 200 mg qid for 2 weeks; dosing with meals and at night); 83 were given a standard prescription for triple therapy (dispensed in bottles) and 47 were given a medication pack with times of dosing clearly marked." | 1.29 | An audit of low dose triple therapy for eradication of Helicobacter pylori. ( Ali, MR; Chua, LE; Fraser, AG; Hollis, B; Little, SV; Moore, L, 1996) |
| "Pre-treatment metronidazole susceptible H pylori were significantly more likely to respond to the triple therapy used than those with the metronidazole resistant ones (14 of 15 v five of 10) (p = 0." | 1.29 | Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. ( Ching, CK; Lai, CL; Lai, KC; Lam, SK; Leung, KP; Wong, BC; Yung, RW, 1996) |
| "Its relationship to gastritis has not been studied." | 1.29 | Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease. ( Beattie, AD; Curry, GW; Morton, R; Park, RH; Taha, AS, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (3.14) | 18.7374 |
| 1990's | 120 (47.06) | 18.2507 |
| 2000's | 88 (34.51) | 29.6817 |
| 2010's | 31 (12.16) | 24.3611 |
| 2020's | 8 (3.14) | 2.80 |
| Authors | Studies |
|---|---|
| Gisbert, JP | 5 |
| Alcedo, J | 1 |
| Amador, J | 1 |
| Bujanda, L | 1 |
| Calvet, X | 5 |
| Castro-Fernández, M | 1 |
| Fernández-Salazar, L | 1 |
| Gené, E | 2 |
| Lanas, Á | 1 |
| Lucendo, AJ | 1 |
| Molina-Infante, J | 2 |
| Nyssen, OP | 1 |
| Pérez-Aisa, A | 2 |
| Puig, I | 1 |
| Zhou, Y | 1 |
| Li, T | 1 |
| Zhang, W | 2 |
| Gui, Q | 1 |
| Chen, J | 2 |
| Yu, D | 1 |
| Su, W | 1 |
| Zhu, C | 1 |
| Liang, X | 2 |
| Lu, H | 2 |
| Vu, TB | 1 |
| Tran, TNQ | 1 |
| Tran, TQA | 1 |
| Vu, DL | 1 |
| Hoang, VT | 1 |
| Guevara, B | 1 |
| Cogdill, AG | 1 |
| Thieu, H | 1 |
| Bach Dat, B | 1 |
| Nam, NH | 1 |
| Reda, A | 1 |
| Duc, NT | 1 |
| Alshareef, A | 1 |
| Nguyen, JG | 1 |
| Ngoc, NM | 1 |
| Tien Huy, N | 1 |
| Tang, Y | 1 |
| Tang, G | 1 |
| Pan, L | 1 |
| Zhu, H | 1 |
| Zhou, S | 1 |
| Wei, Z | 1 |
| Van Thieu, H | 1 |
| Duc, NM | 1 |
| Nghi, BTD | 1 |
| Van Bach, N | 1 |
| Khoi, HH | 1 |
| Tien, VNT | 1 |
| Bang, MTL | 1 |
| Ngoc, TLC | 1 |
| Yurenev, GL | 1 |
| Partzvania-Vinogradova, EV | 1 |
| Andreev, DN | 1 |
| Dicheva, DT | 1 |
| Maiev, IV | 1 |
| Malfertheiner, P | 3 |
| Seyedmajidi, S | 1 |
| Mirsattari, D | 1 |
| Zojaji, H | 1 |
| Zanganeh, E | 1 |
| Seyyedmajidi, M | 1 |
| Almasi, S | 1 |
| Zali, M | 1 |
| Sierra, F | 1 |
| Forero, JD | 1 |
| Rey, M | 1 |
| Botero, ML | 1 |
| Cárdenas, A | 1 |
| McNicholl, AG | 1 |
| Marin, AC | 1 |
| Castro, M | 1 |
| Barrio, J | 1 |
| Ducons, J | 2 |
| de la Coba, C | 1 |
| Montoro, M | 2 |
| Bory, F | 2 |
| Forné, M | 1 |
| Onal, IK | 1 |
| Gokcan, H | 1 |
| Benzer, E | 1 |
| Bilir, G | 1 |
| Oztas, E | 1 |
| Kim, SG | 1 |
| Jung, HK | 1 |
| Lee, HL | 1 |
| Jang, JY | 1 |
| Lee, H | 1 |
| Kim, CG | 1 |
| Shin, WG | 1 |
| Shin, ES | 1 |
| Lee, YC | 1 |
| Kim, MS | 1 |
| Kim, N | 5 |
| Kim, SE | 1 |
| Jo, HJ | 1 |
| Shin, CM | 2 |
| Park, YS | 2 |
| Lee, DH | 4 |
| Tu, S | 1 |
| Yang, H | 1 |
| Chung, KH | 1 |
| Jin, E | 1 |
| Cho, Y | 1 |
| Seo, JY | 1 |
| Jeong, SH | 1 |
| Kim, JW | 2 |
| Hwang, JH | 2 |
| Scherübl, H | 1 |
| Fischbach, W | 1 |
| Glocker, E | 1 |
| Andrianov, M | 1 |
| Rivera, E | 1 |
| Azzam, R | 1 |
| Bai, P | 1 |
| Zhou, LY | 1 |
| Xiao, XM | 1 |
| Luo, Y | 1 |
| Ding, Y | 1 |
| Tepeš, B | 1 |
| Vujasinović, M | 1 |
| Šeruga, M | 1 |
| Stefanovič, M | 1 |
| Forte, A | 1 |
| Jeverica, S | 1 |
| Murakami, K | 6 |
| Sakurai, Y | 1 |
| Shiino, M | 1 |
| Funao, N | 1 |
| Nishimura, A | 1 |
| Asaka, M | 3 |
| Hu, B | 1 |
| Zhao, F | 1 |
| Wang, S | 1 |
| Olszewski, MA | 1 |
| Bian, H | 1 |
| Wu, Y | 1 |
| Kong, M | 1 |
| Xu, L | 1 |
| Miao, Y | 1 |
| Fang, Y | 1 |
| Yang, C | 1 |
| Zhao, H | 1 |
| Zhang, Y | 1 |
| Georgopoulos, SD | 1 |
| Xirouchakis, E | 1 |
| Martinez-Gonzales, B | 1 |
| Zampeli, E | 1 |
| Grivas, E | 1 |
| Spiliadi, C | 1 |
| Sotiropoulou, M | 1 |
| Petraki, K | 1 |
| Zografos, K | 1 |
| Laoudi, F | 1 |
| Sgouras, D | 1 |
| Mentis, A | 1 |
| Kasapidis, P | 1 |
| Michopoulos, S | 1 |
| Legendre, T | 1 |
| Boudebesse, C | 1 |
| Henry, C | 1 |
| Etain, B | 1 |
| Lin, LC | 1 |
| Hsu, TH | 1 |
| Huang, KW | 1 |
| Tam, KW | 1 |
| Chen, Q | 1 |
| Fu, Q | 1 |
| Liu, W | 1 |
| Xiao, S | 1 |
| Oyedeji, KS | 1 |
| Smith, SI | 1 |
| Coker, AO | 1 |
| Arigbabu, AO | 1 |
| Abdou, AG | 1 |
| Elshayeb, EI | 1 |
| Farag, AG | 1 |
| Elnaidany, NF | 1 |
| Singh, V | 1 |
| Mishra, S | 1 |
| Maurya, P | 1 |
| Rao, G | 1 |
| Jain, AK | 1 |
| Dixit, VK | 1 |
| Gulati, AK | 1 |
| Nath, G | 1 |
| Kim, JJ | 1 |
| Choe, YH | 1 |
| Kim, HS | 1 |
| Kim, JI | 1 |
| Chung, IS | 1 |
| Kivistö, R | 1 |
| Linros, J | 1 |
| Rossi, M | 1 |
| Rautelin, H | 3 |
| Hänninen, ML | 1 |
| Gawrońska-Szklarz, B | 2 |
| Siuda, A | 2 |
| Kurzawski, M | 2 |
| Bielicki, D | 1 |
| Marlicz, W | 1 |
| Droździk, M | 2 |
| Ben Mansour, K | 1 |
| Burucoa, C | 1 |
| Zribi, M | 1 |
| Masmoudi, A | 1 |
| Karoui, S | 1 |
| Kallel, L | 1 |
| Chouaib, S | 1 |
| Matri, S | 1 |
| Fekih, M | 1 |
| Zarrouk, S | 1 |
| Labbene, M | 1 |
| Boubaker, J | 1 |
| Cheikh, I | 1 |
| Hriz, MB | 1 |
| Siala, N | 1 |
| Ayadi, A | 1 |
| Filali, A | 1 |
| Mami, NB | 1 |
| Najjar, T | 1 |
| Maherzi, A | 1 |
| Sfar, MT | 1 |
| Fendri, C | 1 |
| Kampitak, T | 1 |
| Koizumi, W | 1 |
| Tanabe, S | 1 |
| Nakatani, K | 1 |
| Ishido, K | 1 |
| Nishimura, K | 1 |
| Azuma, M | 1 |
| Ae, T | 1 |
| Sasaki, T | 1 |
| Higuchi, K | 1 |
| Katada, C | 1 |
| Nakayama, N | 1 |
| Saigenji, K | 1 |
| Riahizadeh, S | 1 |
| Malekzadeh, R | 2 |
| Agah, S | 1 |
| Zendehdel, N | 1 |
| Sotoudehmanesh, R | 1 |
| Ebrahimi-Dariani, N | 1 |
| Pourshams, A | 1 |
| Vahedi, H | 2 |
| Mikaeli, J | 1 |
| Khatibian, M | 1 |
| Massarrat, S | 2 |
| Bytzer, P | 1 |
| Dahlerup, JF | 1 |
| Eriksen, JR | 1 |
| Jarbøl, DE | 1 |
| Rosenstock, S | 1 |
| Wildt, S | 1 |
| Park, HG | 1 |
| Jung, MK | 1 |
| Jung, JT | 1 |
| Kwon, JG | 1 |
| Kim, EY | 1 |
| Seo, HE | 1 |
| Lee, JH | 2 |
| Yang, CH | 1 |
| Kim, ES | 1 |
| Cho, KB | 1 |
| Park, KS | 1 |
| Lee, SH | 1 |
| Kim, KO | 1 |
| Jeon, SW | 1 |
| Shcherbakov, PL | 1 |
| Ianova, OB | 1 |
| Belousova, NL | 1 |
| Masharova, AA | 1 |
| Shcherbakova, MIu | 1 |
| Goncharenko, LS | 1 |
| Firsova, LD | 1 |
| Kim, VA | 1 |
| Govorun, VM | 1 |
| Kashnikov, VS | 1 |
| Figura, N | 1 |
| Moretti, E | 1 |
| Vaglio, L | 1 |
| Langone, F | 1 |
| Vernillo, R | 1 |
| Vindigni, C | 1 |
| Giordano, N | 1 |
| Shah, A | 1 |
| Javid, G | 1 |
| Zargar, SA | 1 |
| Teli, F | 1 |
| Khan, BA | 1 |
| Yattoo, GN | 1 |
| Gulzar, GM | 1 |
| Sodhi, JS | 1 |
| Khan, MA | 1 |
| Shoukat, A | 1 |
| Saif, R | 1 |
| Guardiola, J | 1 |
| Tito, L | 1 |
| Andreu, V | 1 |
| Guirao, R | 2 |
| Boixeda, D | 2 |
| Bermejo, F | 1 |
| Martín-De-Argila, C | 1 |
| López-Sanromán, A | 1 |
| Defarges, V | 1 |
| Hernández-Ranz, F | 1 |
| Milicua, JM | 1 |
| García-Plaza, A | 1 |
| Schuster, MJ | 1 |
| Olafsson, S | 3 |
| Hatlebakk, JG | 4 |
| Berstad, A | 6 |
| Toro, C | 1 |
| García-Samaniego, J | 1 |
| Alarcón, T | 1 |
| Baquero, M | 1 |
| Eun, CS | 2 |
| Han, DS | 2 |
| Park, JY | 1 |
| Jeon, YC | 2 |
| Hahm, JS | 2 |
| Kim, KS | 1 |
| Kang, JO | 2 |
| Unge, P | 1 |
| Kimura, K | 2 |
| Sipponen, P | 2 |
| Ekström, P | 1 |
| Satoh, K | 1 |
| Hellblom, M | 1 |
| Ohlin, B | 1 |
| Stubberöd, A | 1 |
| Kihira, K | 2 |
| Yube, T | 1 |
| Yoshida, Y | 2 |
| Laine, L | 3 |
| Bakumov, PA | 1 |
| Shchepotkin, IV | 1 |
| Dugina, YL | 1 |
| Epstein, OI | 1 |
| Sergeeva, SA | 1 |
| Lui, SY | 1 |
| Yeoh, KG | 2 |
| Ho, B | 2 |
| Neuhann, HF | 1 |
| Swai, B | 1 |
| Carpenter, CF | 1 |
| Shao, O | 1 |
| Bochenek, WJ | 1 |
| Peters, S | 1 |
| Fraga, PD | 1 |
| Wang, W | 1 |
| Mack, ME | 1 |
| Osato, MS | 2 |
| El-Zimaity, HM | 3 |
| Davis, KD | 1 |
| Graham, DY | 7 |
| Gambaro, C | 1 |
| Bilardi, C | 1 |
| Dulbecco, P | 1 |
| Iiritano, E | 1 |
| Zentilin, P | 1 |
| Mansia, C | 1 |
| Usai, P | 1 |
| Vigneri, S | 1 |
| Savarino, V | 2 |
| Thyagarajan, SP | 1 |
| Ray, P | 1 |
| Das, BK | 1 |
| Ayyagari, A | 2 |
| Khan, AA | 1 |
| Dharmalingam, S | 1 |
| Rao, UA | 1 |
| Rajasambandam, P | 1 |
| Ramathilagam, B | 1 |
| Bhasin, D | 1 |
| Sharma, MP | 2 |
| Naik, SR | 1 |
| Habibullah, CM | 1 |
| Färkkilä, M | 2 |
| Sarna, S | 1 |
| Valtonen, V | 1 |
| Bhatia, V | 1 |
| Ahuja, V | 1 |
| Das, B | 1 |
| Bal, C | 1 |
| Fraser, A | 1 |
| Wheeldon, TU | 1 |
| Granström, M | 1 |
| Hoang, TT | 1 |
| Phuncarg, DC | 1 |
| Nilsson, LE | 1 |
| Sörberg, M | 2 |
| Janssen, MJ | 2 |
| Laheij, RJ | 2 |
| Jansen, JB | 2 |
| de Boer, WA | 11 |
| Schuster, M | 1 |
| Saad, R | 1 |
| Chey, WD | 2 |
| Hu, YY | 1 |
| Zhou, ZF | 1 |
| Nan, Q | 1 |
| Jiang, HY | 1 |
| Zhang, L | 1 |
| Li, XY | 1 |
| Duan, LP | 1 |
| Chen, YR | 1 |
| Sun, WH | 1 |
| Ou, XL | 1 |
| Cao, DZ | 1 |
| Yu, Q | 1 |
| Yu, T | 1 |
| Hu, JM | 1 |
| Zhu, F | 1 |
| Sun, YL | 1 |
| Fu, XL | 1 |
| Su, H | 1 |
| Cheon, JH | 1 |
| Park, MJ | 1 |
| Kim, JM | 1 |
| Kim, JS | 1 |
| Jung, HC | 2 |
| Song, IS | 2 |
| Chen, FB | 1 |
| Yu, JD | 1 |
| Chen, XJ | 1 |
| Li, ZY | 1 |
| Zhang, XP | 1 |
| Albert, TJ | 1 |
| Dailidiene, D | 1 |
| Dailide, G | 1 |
| Norton, JE | 1 |
| Kalia, A | 1 |
| Richmond, TA | 1 |
| Molla, M | 1 |
| Singh, J | 1 |
| Green, RD | 1 |
| Berg, DE | 1 |
| Matsushima, M | 1 |
| Suzuki, T | 1 |
| Kurumada, T | 2 |
| Watanabe, S | 2 |
| Watanabe, K | 3 |
| Kobayashi, K | 1 |
| Deguchi, R | 1 |
| Masui, A | 1 |
| Takagi, A | 2 |
| Shirai, T | 2 |
| Muraoka, H | 2 |
| Kobayashi, I | 2 |
| Mine, T | 1 |
| Sato, R | 3 |
| Okimoto, T | 3 |
| Nasu, M | 1 |
| Fujioka, T | 4 |
| Kodama, M | 3 |
| Abe, T | 1 |
| Sato, S | 1 |
| Arita, T | 1 |
| Butorov, IV | 2 |
| Osoianu, IuP | 2 |
| Butorov, SI | 2 |
| Maksimov, VV | 2 |
| Koletzko, S | 1 |
| Richy, F | 1 |
| Bontems, P | 1 |
| Crone, J | 1 |
| Kalach, N | 1 |
| Monteiro, ML | 1 |
| Gottrand, F | 1 |
| Celinska-Cedro, D | 1 |
| Roma-Giannikou, E | 1 |
| Orderda, G | 1 |
| Kolacek, S | 1 |
| Urruzuno, P | 1 |
| Martínez-Gómez, MJ | 1 |
| Casswall, T | 1 |
| Ashorn, M | 1 |
| Bodanszky, H | 1 |
| Mégraud, F | 1 |
| Díte, P | 1 |
| Kunovská, M | 1 |
| Pulgretová, D | 1 |
| Woznica, V | 1 |
| Petrtýl, J | 1 |
| Hůlek, P | 1 |
| Pásková, J | 1 |
| Dostalík, Z | 1 |
| Novotný, I | 1 |
| Procházka, V | 1 |
| Hegyi, P | 1 |
| Zelenková, J | 1 |
| Samek, M | 1 |
| Králová, Z | 1 |
| Vyhnálek, P | 1 |
| Matejovic, F | 1 |
| Weinberg, J | 1 |
| Kyzeková, J | 1 |
| Hendrikse, L | 1 |
| de Boer, SY | 2 |
| Bosboom, R | 1 |
| Wrześniewska, J | 1 |
| Starzyńska, T | 1 |
| Dzieniszewski, J | 1 |
| Jarosz, M | 1 |
| Emami, MH | 1 |
| Saberfiroozi, MM | 1 |
| Arj, A | 1 |
| Taghavi, AR | 1 |
| Bagheri-Lankarani, K | 1 |
| Dehbashi, N | 1 |
| Fattahi, MR | 1 |
| Alizadeh, M | 1 |
| Kaviani, MJ | 2 |
| Bahri-Najafi, R | 1 |
| Geramizadeh, B | 1 |
| Esmaeili, A | 1 |
| Chung, SJ | 1 |
| Jung, SH | 1 |
| Lee, KH | 1 |
| Fuccio, L | 1 |
| Minardi, ME | 1 |
| Zagari, RM | 1 |
| Grilli, D | 1 |
| Magrini, N | 1 |
| Bazzoli, F | 1 |
| Bang, SY | 1 |
| Kim, JE | 1 |
| Ahn, SB | 1 |
| Sohn, JH | 1 |
| Hansen, JM | 1 |
| Wildner-Christensen, M | 1 |
| Hallas, J | 1 |
| Schaffalitzky de Muckadell, OB | 1 |
| Baker, DE | 1 |
| Bjørneklett, A | 1 |
| Fausa, O | 1 |
| Midtvedt, T | 1 |
| Shirokova, KI | 1 |
| Filimonov, RM | 1 |
| Poliakova, LV | 1 |
| Domschke, W | 1 |
| Dettmer, A | 1 |
| Fenner, T | 1 |
| Gregor, M | 1 |
| Hesse, P | 1 |
| Holtmann, G | 1 |
| van Husen, N | 1 |
| Miederer, SE | 1 |
| Schentke, KU | 1 |
| Schütz, E | 1 |
| Berstad, K | 5 |
| Wilhelmsen, I | 4 |
| Nesje, LB | 3 |
| Hausken, T | 4 |
| Tytgat, GN | 8 |
| O'Connor, HJ | 3 |
| Kanduru, C | 1 |
| Bhutta, AS | 2 |
| Meehan, JM | 1 |
| Feeley, KM | 1 |
| Cunnane, K | 3 |
| Park, KN | 1 |
| Kim, HJ | 1 |
| Cohen, MH | 1 |
| Treiber, G | 2 |
| Klotz, O | 1 |
| Adamek, RJ | 3 |
| Opferkuch, W | 1 |
| Wegener, M | 1 |
| Goddard, A | 1 |
| Logan, R | 1 |
| Labenz, J | 5 |
| Stolte, M | 2 |
| Rühl, GH | 3 |
| Becker, T | 2 |
| Tillenburg, B | 2 |
| Sollböhmer, M | 1 |
| Börsch, G | 5 |
| Harris, A | 1 |
| Misiewicz, JJ | 1 |
| de Boer, W | 1 |
| Driessen, W | 1 |
| Jansz, A | 1 |
| Tytgat, G | 1 |
| Marshall, BJ | 1 |
| Bertrams, J | 1 |
| Ohtaki, T | 1 |
| Kato, M | 2 |
| Kudo, M | 2 |
| Kimura, T | 1 |
| Meguro, T | 1 |
| Horita, S | 1 |
| Inoue, K | 1 |
| Nysaeter, G | 2 |
| Bang, CJ | 2 |
| Hjartholm, AS | 1 |
| Hundal, O | 4 |
| Goh, KL | 1 |
| Peh, SC | 1 |
| Parasakthi, N | 1 |
| Wong, NW | 1 |
| Tan, KK | 1 |
| Lo, YL | 1 |
| Tee, W | 1 |
| Seppälä, K | 2 |
| Kosunen, TU | 2 |
| Axon, AT | 1 |
| Peura, DA | 1 |
| Wagner, S | 1 |
| Haruma, K | 1 |
| Gladziwa, U | 1 |
| Soudah, B | 1 |
| Gebel, M | 1 |
| Bleck, J | 1 |
| Schmidt, H | 1 |
| Manns, M | 1 |
| Weberg, R | 1 |
| Go, MF | 1 |
| Lew, GM | 2 |
| Genta, RM | 2 |
| Rehfeld, JF | 1 |
| Jaspersen, D | 1 |
| Hammar, CH | 1 |
| Thijs, JC | 3 |
| Van Zwet, AA | 3 |
| Oey, HB | 1 |
| Hepps, KS | 1 |
| Ramirez, FC | 1 |
| Saeed, ZA | 1 |
| Tucci, A | 1 |
| Corinaldesi, R | 1 |
| Stanghellini, V | 1 |
| Paparo, GF | 1 |
| Gasperoni, S | 1 |
| Biasco, G | 1 |
| Varoli, O | 1 |
| Ricci-Maccarini, M | 1 |
| Barbara, L | 1 |
| Sharma, S | 1 |
| Prasad, KN | 1 |
| Chamoli, D | 1 |
| Karita, M | 1 |
| Tsuda, M | 1 |
| Okita, K | 1 |
| Sugiyama, T | 2 |
| Nakazawa, T | 1 |
| Götz, JM | 1 |
| Veenendaal, RA | 1 |
| Veselic, M | 1 |
| Bernards, S | 1 |
| Lamers, CB | 1 |
| Soll, AH | 1 |
| Tefera, S | 2 |
| Taha, AS | 1 |
| Curry, GW | 1 |
| Morton, R | 1 |
| Park, RH | 1 |
| Beattie, AD | 1 |
| Ching, CK | 1 |
| Leung, KP | 1 |
| Yung, RW | 1 |
| Lam, SK | 1 |
| Wong, BC | 1 |
| Lai, KC | 1 |
| Lai, CL | 1 |
| Peitz, U | 1 |
| Fraser, AG | 1 |
| Moore, L | 1 |
| Ali, MR | 1 |
| Chua, LE | 1 |
| Hollis, B | 1 |
| Little, SV | 1 |
| Bergseth, M | 1 |
| Gabryelewicz, A | 1 |
| Driessen, WM | 4 |
| Jansz, AR | 1 |
| Dammann, HG | 1 |
| Lai, JY | 3 |
| Geuskens, LM | 1 |
| Weel, JF | 2 |
| van der Hulst, RW | 2 |
| Gerrits, Y | 1 |
| van der Ende, A | 2 |
| Dankert, J | 2 |
| Yousfi, MM | 1 |
| Cole, RA | 1 |
| ten Kate, FJ | 1 |
| Wang, K | 1 |
| Lin, HJ | 1 |
| Chua, RT | 1 |
| Perng, CL | 2 |
| Tsay, SH | 1 |
| Lee, SD | 1 |
| Gomollón, F | 4 |
| Gimeno, L | 1 |
| Valdepérez, J | 1 |
| Yus, C | 1 |
| Marzo, J | 1 |
| Pérez-Caballero, MC | 1 |
| Patchin, GM | 1 |
| Wieland, KA | 1 |
| Carmichael, JM | 1 |
| Vautier, G | 1 |
| Scott, BB | 1 |
| van Etten, RJ | 3 |
| Schade, RW | 1 |
| Ouwehand, ME | 1 |
| Schneeberger, PM | 4 |
| van Unnik, AJ | 1 |
| Miederer, S | 1 |
| Ström, M | 1 |
| Jönsson, KA | 1 |
| Annibale, B | 1 |
| D'Ambra, G | 1 |
| Luzzi, I | 1 |
| Marcheggiano, A | 1 |
| Iannoni, C | 1 |
| Paoletti, M | 1 |
| Anania, MC | 1 |
| Marignani, M | 1 |
| Delle Fave, G | 1 |
| MacConnachie, AM | 1 |
| Damianos, AJ | 1 |
| McGarrity, TJ | 1 |
| Forbes, GM | 1 |
| Fock, KM | 2 |
| Myers, D | 1 |
| Bateson, MC | 1 |
| Winn, G | 1 |
| Ahmad, F | 1 |
| Fisher, L | 1 |
| Elta, GH | 1 |
| Barnett, JL | 1 |
| Nostrant, T | 1 |
| DelValle, J | 1 |
| Hasler, WL | 1 |
| Scheiman, JM | 2 |
| Szymanski, C | 2 |
| Pfaffenbach, B | 2 |
| Moayyedi, P | 2 |
| van de Wouw, BA | 1 |
| Estrada, R | 1 |
| Trujillo, M | 1 |
| Emami, S | 1 |
| Carpintero, P | 1 |
| Blanco, M | 1 |
| Pajares, JM | 3 |
| Loane, J | 1 |
| Bindel, H | 1 |
| Korman, MG | 2 |
| Bolin, TD | 2 |
| Engelman, JL | 2 |
| Pianko, S | 1 |
| Lerang, F | 1 |
| Moum, B | 1 |
| Ragnhildstveit, E | 1 |
| Sandvei, PK | 1 |
| Tolås, P | 1 |
| Whist, JE | 1 |
| Henriksen, M | 1 |
| Haug, JB | 1 |
| Berge, T | 1 |
| Metz, DC | 1 |
| el-Nujumi, A | 3 |
| Williams, C | 1 |
| Ardill, JE | 1 |
| Oien, K | 1 |
| McColl, KE | 3 |
| Kim, JG | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Blum, AL | 1 |
| Sheu, BS | 1 |
| Wu, JJ | 1 |
| Yang, HB | 1 |
| Huang, AH | 1 |
| Lin, XZ | 1 |
| Fireman, Z | 1 |
| Segal, A | 1 |
| Moshkowitz, M | 1 |
| Kopelman, Y | 1 |
| Sternberg, A | 1 |
| García, N | 2 |
| Campo, R | 2 |
| Brullet, E | 2 |
| Comet, R | 1 |
| Navarro, M | 1 |
| Kubota, T | 1 |
| Tokushima, H | 1 |
| Tamura, H | 1 |
| Murakawa, M | 1 |
| Matsumura, O | 1 |
| Itakura, Y | 1 |
| Itoyama, S | 1 |
| Mitarai, T | 1 |
| Isoda, K | 1 |
| Murray, LS | 1 |
| el-Omar, EM | 1 |
| Dickson, A | 2 |
| Kelman, AW | 1 |
| Hilditch, TE | 1 |
| Siem, TH | 1 |
| Jeffries, MA | 1 |
| Fendrick, AM | 1 |
| Chiba, N | 1 |
| Lahaie, R | 1 |
| Fedorak, RN | 1 |
| Bailey, R | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Bernucci, B | 1 |
| van der Wouden, EJ | 2 |
| Kooy, A | 1 |
| Kleibeuker, JH | 2 |
| Nicholson, FB | 1 |
| Stack, WA | 1 |
| Knifton, A | 1 |
| Thirlwell, D | 1 |
| Cockayne, A | 1 |
| Jenkins, D | 1 |
| Hawkey, CJ | 1 |
| Atherton, JC | 1 |
| Okada, M | 1 |
| Oki, K | 1 |
| Shirotani, T | 1 |
| Seo, M | 1 |
| Okabe, N | 1 |
| Maeda, K | 1 |
| Nishimura, H | 1 |
| Ohkuma, K | 1 |
| Oda, K | 1 |
| Hua, J | 1 |
| Ng, HC | 1 |
| Ho, KY | 1 |
| Shuter, J | 1 |
| Fletcher, DD | 1 |
| Simone, VJ | 1 |
| Bellin, EY | 1 |
| Lee, CL | 1 |
| Tu, TC | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Chan, CC | 1 |
| Huang, SH | 1 |
| Lee, SC | 1 |
| Kimoto, M | 1 |
| Sekine, H | 1 |
| Ohara, S | 1 |
| Iijima, K | 1 |
| Kato, K | 1 |
| Iwasaki, A | 1 |
| Kouda, K | 1 |
| Tada, U | 1 |
| Wada, T | 1 |
| Harasawa, S | 1 |
| Miwa, T | 1 |
| Sato, K | 2 |
| Kumakura, Y | 1 |
| Sugano, K | 1 |
| Kung, NN | 1 |
| Sung, JJ | 2 |
| Yuen, NW | 1 |
| Li, TH | 1 |
| Ng, PW | 1 |
| Lai, WM | 1 |
| Lui, YH | 1 |
| Lam, KN | 1 |
| Choi, CH | 1 |
| Leung, EM | 1 |
| Navuluri, R | 1 |
| Yue, S | 1 |
| Lin, CW | 1 |
| Chang, YS | 1 |
| Wu, SC | 1 |
| Cheng, KS | 1 |
| Pilotto, A | 1 |
| Franceschi, M | 1 |
| Leandro, G | 1 |
| Bozzola, L | 1 |
| Fortunato, A | 1 |
| Rassu, M | 1 |
| Meli, S | 1 |
| Soffiati, G | 1 |
| Scagnelli, M | 1 |
| Di Mario, F | 1 |
| Valerio, G | 1 |
| Grimley, CE | 1 |
| Penny, A | 1 |
| O'sullivan, M | 1 |
| Shebani, M | 1 |
| Lismore, JR | 1 |
| Cross, R | 1 |
| Illing, RC | 1 |
| Loft, DE | 1 |
| Nwokolo, CU | 1 |
| Houben, MH | 1 |
| Hensen, EF | 1 |
| Rauws, EA | 1 |
| Hulst, RW | 1 |
| Hoff, BW | 1 |
| Ende, AV | 1 |
| Kate, FJ | 1 |
| Chan, FK | 1 |
| Wu, JC | 1 |
| Leung, WK | 1 |
| Suen, R | 1 |
| Ling, TK | 1 |
| Lee, YT | 1 |
| Cheng, AF | 1 |
| Chung, SC | 1 |
| Ellenrieder, V | 1 |
| Boeck, W | 1 |
| Richter, C | 1 |
| Marre, R | 1 |
| Adler, G | 1 |
| Glasbrenner, B | 1 |
| Boyanova, L | 2 |
| de Grauw, WJ | 1 |
| Tanigawara, Y | 1 |
| Aoyama, N | 1 |
| Kita, T | 1 |
| Shirakawa, K | 1 |
| Komada, F | 1 |
| Kasuga, M | 1 |
| Okumura, K | 1 |
| Ducóns, JA | 3 |
| Ferrero, M | 3 |
| García Cabezudo, J | 1 |
| Simón, MA | 1 |
| Nishikawa, K | 1 |
| Ishizuka, J | 1 |
| Kudo, T | 1 |
| Komatsu, Y | 1 |
| Katagiri, M | 1 |
| Sukegawa, M | 1 |
| Kagaya, H | 1 |
| Takeda, H | 1 |
| Toyota, J | 1 |
| El-Omar, E | 1 |
| Kelman, A | 1 |
| Taskin, V | 1 |
| Gurer, I | 1 |
| Ozyilkan, E | 1 |
| Sare, M | 1 |
| Hilmioglu, F | 1 |
| van Doorn, LJ | 2 |
| Nouhan, N | 1 |
| Plaisier, AP | 1 |
| Quint, WG | 1 |
| Lõivukene, K | 1 |
| Kolk, H | 1 |
| Maaroos, HI | 1 |
| Kasenõmm, P | 1 |
| Ustav, M | 1 |
| Mikelsaar, M | 1 |
| Adamsson, I | 1 |
| Edlund, C | 1 |
| Nord, CE | 1 |
| Stancheva, I | 1 |
| Spassova, Z | 1 |
| Katzarov, N | 1 |
| Mitov, I | 1 |
| Koumanova, R | 1 |
| Azuma, T | 1 |
| Ito, S | 1 |
| Suto, H | 1 |
| Ito, Y | 1 |
| Miyaji, H | 1 |
| Yamazaki, Y | 1 |
| Kato, T | 1 |
| Kuriyama, M | 1 |
| Teo, EK | 1 |
| Ng, TM | 1 |
| Khor, CJ | 1 |
| Tan, AL | 1 |
| Piqué, JM | 1 |
| Romero Gómez, M | 1 |
| Martínez Delgado, C | 1 |
| Grande, L | 1 |
| Otero Fernández, MA | 1 |
| Vargas, J | 1 |
| Castro Fernández, M | 1 |
| Sicilia, B | 2 |
| Sierra, E | 2 |
| Revillo, MJ | 1 |
| Giannini, E | 1 |
| Romagnoli, P | 1 |
| Fasoli, A | 1 |
| Chiarbonello, B | 1 |
| Malfatti, F | 1 |
| Botta, F | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Testa, R | 1 |
| Bezborodnyĭ, SD | 1 |
| Santolaria, S | 1 |
| María Pajares, J | 1 |
| Katelaris, PH | 1 |
| Satoh, R | 1 |
| Kagawa, J | 1 |
| Avidan, B | 1 |
| Melzer, E | 1 |
| Keller, N | 1 |
| Bar-Meir, S | 1 |
| Sanfeliu, I | 1 |
| Murphy, B | 1 |
| Kusters, JG | 1 |
| Kuipers, EJ | 1 |
| Nagahara, A | 1 |
| Miwa, H | 1 |
| Ohkura, R | 1 |
| Yamada, T | 1 |
| Hojo, M | 1 |
| Sato, N | 1 |
| Bardhan, KD | 1 |
| Morton, D | 1 |
| Perry, MJ | 1 |
| Sanders, DS | 1 |
| Morris, P | 1 |
| Rowland, A | 1 |
| Thompson, M | 1 |
| Mitchell, TR | 1 |
| Roberts, PM | 1 |
| Sotoudeh, M | 1 |
| Kamalian, N | 1 |
| Amini, M | 1 |
| Sazhin, VP | 1 |
| Fedorov, AV | 1 |
| Maev, IV | 1 |
| Samsonov, A | 1 |
| Val'tova, ED | 1 |
| Ismailova, MZ | 1 |
| Ovchinnikova, NI | 1 |
| Hildebrand, P | 1 |
| Bardhan, P | 1 |
| Rossi, L | 1 |
| Parvin, S | 1 |
| Rahman, A | 1 |
| Arefin, MS | 1 |
| Hasan, M | 1 |
| Ahmad, MM | 1 |
| Glatz-Krieger, K | 1 |
| Terracciano, L | 1 |
| Bauerfeind, P | 1 |
| Beglinger, C | 1 |
| Gyr, N | 1 |
| Khan, AK | 1 |
| Tankovic, J | 1 |
| Lamarque, D | 1 |
| Lascols, C | 1 |
| Soussy, CJ | 1 |
| Delchier, JC | 1 |
| Marcos, S | 1 |
| Gisbert, JL | 1 |
| He, JX | 1 |
| Akao, T | 1 |
| Nishino, T | 1 |
| Tani, T | 1 |
| Wittig, J | 1 |
| Ammon, S | 1 |
| Walker, S | 1 |
| Klotz, U | 1 |
| Yamamoto, N | 1 |
| Sakagami, T | 1 |
| Fukuda, Y | 1 |
| Shimoyama, T | 1 |
| Fu, HY | 1 |
| Kawano, S | 1 |
| Tanimura, H | 1 |
| Hiraishi, H | 1 |
| Kanke, K | 1 |
| Terano, A | 1 |
| Kuwayama, H | 1 |
| Takahashi, M | 1 |
| Suzuki, K | 1 |
| Suga, M | 1 |
| Takata, H | 1 |
| Ohara, T | 1 |
| Koizumi, K | 1 |
| Kiriyama, Y | 1 |
| Cuchí Burgos, E | 1 |
| Forné Bardera, M | 1 |
| Quintana Riera, S | 1 |
| Lite Lite, J | 1 |
| Garau Alemany, J | 1 |
| Harikrishnan, P | 1 |
| Bindayna, KM | 1 |
| Hasegawa, M | 1 |
| Saika, T | 1 |
| Nishida, M | 1 |
| Kawamura, M | 1 |
| Ando, R | 1 |
| Skornetskiĭ, BD | 2 |
| Gavrilenko, IaV | 2 |
| Vazilo, VE | 1 |
| Parshkov, EM | 1 |
| Pichugin, IuI | 1 |
| Lebreton, JM | 1 |
| Nuutinen, H | 1 |
| Hakala, K | 1 |
| Väänänen, H | 1 |
| Smoot, DT | 1 |
| Scott, VF | 1 |
| Bhatia, RS | 1 |
| Nigam, P | 1 |
| Lewis, JH | 1 |
| Weingold, AB | 1 |
| Quintero Diaz, M | 1 |
| Sotto Escobar, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [NCT01792700] | Phase 4 | 648 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Comparison of Vonoprazan and Amoxicillin Dual Therapy With Standard Triple Therapy With Proton Pump Inhibitor for Helicobacter Pylori Eradication; a Randomized Control Trial[NCT04901663] | Phase 4 | 179 participants (Actual) | Interventional | 2021-06-21 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole[NCT01505127] | Phase 3 | 650 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| 10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial[NCT03592069] | Phase 4 | 345 participants (Actual) | Interventional | 2018-02-21 | Completed | ||
| Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance[NCT01453036] | Phase 4 | 924 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding[NCT00687336] | Phase 4 | 178 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | ||
| Comparison of Clinical Outcomes in Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella Pneumoniae (COMBAT)[NCT04229498] | 300 participants (Anticipated) | Observational | 2020-04-30 | Not yet recruiting | |||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Eradication was determined by the C13-urea breath test 6 to 8 weeks after the eradication therapy when PPIs had not been used for at least 2 weeks. (NCT01453036)
Timeframe: 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Convential AOC Group | 75.9 |
| Mutation Test Group | 91.2 |
| Convential AOM Group | 79.1 |
42 reviews available for metronidazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
V Spanish Consensus Conference on Helicobacter pylori infection treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2022 |
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Biopsy; Bismuth; Breath | 2020 |
[What is new in treating Helicobacter pylori infection?].
Topics: Adult; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combi | 2015 |
[Antibiomania: Think of the manic syndrome secondary to antibiotic therapy].
Topics: Amoxicillin; Anti-Bacterial Agents; Bipolar Disorder; Clarithromycin; Drug Therapy, Combination; Fem | 2017 |
Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials.
Topics: Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Disease Eradication; Drug Therapy, Combin | 2016 |
Diagnosis and treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Denmark; Drug Therapy, | 2011 |
[Helicobacter pylori. Update 2002].
Topics: Adenocarcinoma; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2002 |
Is it time for quadruple therapy to be first line?
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Dru | 2003 |
[Helicobacter pylori: reasons for eradication].
Topics: Adenocarcinoma; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastritis | 2004 |
A clinician's guide to managing Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Endoscopy; Gastrointestinal | 2005 |
Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspeps | 2007 |
Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Therapy, Combination; He | 2008 |
Treating peptic ulcer: an ongoing challenge.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combina | 1995 |
[Management of the peptic ulcer patient in the Helicobacter pylori age].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Breath Tests; Child; Drug Therapy, Com | 1994 |
Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 1994 |
The role of acid inhibition in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Depression, Chemical; Drug Administration Schedule; Drug Therapy, Combination; Gastric | 1994 |
Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobac | 1994 |
[Treatment of Helicobacter pylori infection in adults].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Gas | 1994 |
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Biopsy; | 1996 |
Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Follow-Up St | 1996 |
Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combin | 1996 |
[Helicobacter pylori eradication: triple therapy versus dual therapy].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Com | 1996 |
Treatment strategies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combin | 1997 |
Review: Helicobacter pylori. Current issues and new directions.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Therapy, Combination; | 1997 |
Peptic ulcer disease in the 1990s: an Asian perspective.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Asia; Bismu | 1997 |
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.
Topics: Amoxicillin; Antitrichomonal Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Com | 1997 |
[Helicobacter pylori infection and ulcer].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori | 1998 |
[Problems following antibiotic therapy for eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Clarithromycin; Drug Resistance, Microbi | 1998 |
Helicobacter pylori and peptic ulcer disease. Current evidence for management strategies.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Evidence-Based Medicine; Family | 1998 |
[Antibiotic-resistant H. pylori strains in the last ten years in Japan].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infecti | 1999 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Microbial ecology and treatment of Helicobacter pylori infections: review.
Topics: Adenocarcinoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; | 2000 |
[Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review].
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; Helicoba | 2001 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administr | 2001 |
Helicobacter pylori: a clinical update.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combinat | 2001 |
Antibiotic resistance of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infecti | 2001 |
Helicobacter pylori therapy: first-line options and rescue regimen.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combin | 2001 |
[Development of Helicobacter pylori eradication therapy].
Topics: Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobact | 2002 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Sucralfate].
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastric Ac | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarith | 2002 |
The use of gastrointestinal drugs during pregnancy and lactation.
Topics: Adrenal Cortex Hormones; Animals; Antidiarrheals; Antiemetics; Cathartics; Diuretics; Female; Gastro | 1985 |
99 trials available for metronidazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections | 2023 |
Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dru | 2018 |
[Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2013 |
Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Analysis of Variance; Anti-Bact | 2013 |
Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2014 |
Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Disease-Fr | 2013 |
Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Sch | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Breath Tests; Carbon Isotopes; Clarithromyc | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug | 2016 |
Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Double-Blind Meth | 2010 |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
[Enterofuril eradication therapy in chronic inflammatory diseases of the upper digestive tract].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Chronic Disease; Clarithromyc | 2011 |
Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dru | 2013 |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration S | 2002 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Patients with endoscopic gastritis and/or duodenitis improve markedly following eradication of Helicobacter pylori, although less so than patients with ulcers.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenitis; Female; Fo | 2002 |
Do Japanese and Swedish peptic ulcer patients respond differently to Helicobacter pylori eradication therapies and what are their histological features?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Dr | 2003 |
Clinical efficiency of Epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.
Topics: Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Antibodies; Dose-Response Relationship, Drug; Dru | 2003 |
Efficacy of different antibiotic regimens for eradication treatment of Helicobacter pylori infection in peptic ulcer disease in Tanzanian patients.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Sc | 2003 |
Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2003 |
Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Gastrointestinal | 2004 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth | 2004 |
Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Asian People; Clarithromycin | 2005 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
[Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administrat | 2005 |
[Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Meth | 2002 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; | 2006 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Community Health Services; Cost-Benefit Analy | 2008 |
Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up.
Topics: Adult; Aged; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobact | 1995 |
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1994 |
Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Duodenitis; Female; Gastritis; Helicobacter | 1995 |
One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1995 |
Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hel | 1995 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Heli | 1994 |
Omeprazole 40 mg o.m. combined with amoxycillin alone or with amoxycillin and metronidazole in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; | 1994 |
Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease.
Topics: Adult; Aged; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicoba | 1994 |
Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, C | 1993 |
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Hemorrhage; Hel | 1993 |
Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Interactions; Drug Thera | 1995 |
Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bism | 1996 |
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Ant | 1995 |
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Th | 1995 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Heli | 1996 |
Therapeutic options after failed Helicobacter pylori eradication therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 1996 |
Omeprazole plus amoxicillin versus triple therapy eradicates Helicobacter pylori in the Chinese with peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter pylori; | 1996 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 1997 |
Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Fe | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1997 |
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1997 |
Quadruple therapy: the golden bullet or a drug too far?
Topics: Antacids; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicob | 1996 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Protein | 1996 |
Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Test | 1997 |
Ranitidine versus colloidal bismuth subcitrate in combination with amoxicillin and metronidazole for eradicating Helicobacter pylori in patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 1997 |
One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit?
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1997 |
Sucralfate as an alternative to bismuth in quadruple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Female; Gastritis; Helicobacter Infe | 1997 |
Eradicate the bug before you start the drug?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; | 1998 |
Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment.
Topics: Adult; Alginates; Aluminum Hydroxide; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Combinations; D | 1998 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microb | 1998 |
Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Fema | 1998 |
Helicobacter pylori eradication: kill the bug and save the pill?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Follow-Up Studies | 1998 |
One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clari | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspe | 1998 |
[Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Follow-Up Studies; Helico | 1999 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1999 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1999 |
One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Sche | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromy | 1999 |
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Helicobacter treatment with quadruple therapy in primary health care for patients with a history of ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combinati | 1999 |
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Re | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, | 2000 |
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2000 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromy | 2000 |
Intravenous eradication therapy for bleeding gastroduodenal ulcer associated with Helicobacter pylori infection.
Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Fem | 2000 |
Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Female; Follo | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ul | 2001 |
Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sch | 2001 |
Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clari | 2001 |
Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy, Needle; Bismuth; Breath Tests; Drug Administratio | 2001 |
[Efficiency of quamatel in combination with device sound stimulation of the gastroduodenal zone in ulcer patients].
Topics: Acoustic Stimulation; Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Antifungal Agents; Combined | 2001 |
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dyspepsia; Female; H | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
[Treatment of duodenal peptic ulcer with metronidazole].
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Duodenal Ul | 1977 |
Metronidazole versus cimetidine in treatment of gastroduodenal ulcer.
Topics: Cimetidine; Clinical Trials as Topic; Female; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer | 1986 |
114 other studies available for metronidazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Effects of Quadruple Therapy Combined with Probiotics on
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrins; Helicobacter Infec | 2022 |
Antibiotic Resistance of
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug | 2022 |
Antibiotic resistance of Helicobacter pylori infection in a children's hospital in Vietnam: prevalence and associated factors.
Topics: Amoxicillin; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Comb | 2020 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2020 |
Antimicrobial Resistance and the Successful Eradication of
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Asian People; Child; Child, Preschool; Clarithromyci | 2021 |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastri | 2013 |
What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Breath Tests; Case-Control Studies; Cla | 2013 |
[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
Topics: Amoxicillin; Anti-Bacterial Agents; Aspirin; Bismuth; Breath Tests; Clarithromycin; Gastroesophageal | 2013 |
[Progress in the treatment of Helicobacter pylori infection].
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Drugs, Chinese Herbal; Gastritis; | 2014 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Ther | 2014 |
A 15-year-old boy with abdominal pain, growth retardation, and anemia secondary to Helicobacter pylori-associated peptic ulcer.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Clarithromycin; Drug Therapy, Combination; Growth | 2015 |
Susceptibility of Helicobacter pylori to antibiotics in Chinese patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Clarithromycin; Drug Resistance, Bacterial; Drug | 2015 |
A high-throughput multiplex genetic detection system for Helicobacter pylori identification, virulence and resistance analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Base Sequence; Biopsy; China; DNA Mutational | 2016 |
Antibiotic susceptibility patterns in Helicobacter pylori strains from patients with upper gastrointestinal pathology in western Nigeria.
Topics: Amoxicillin; Anti-Bacterial Agents; Biopsy; Ciprofloxacin; Clarithromycin; DNA, Bacterial; Drug Resi | 2009 |
Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Biopsy; Case-Control Studies; Chronic Disease; Fema | 2009 |
Drug resistance pattern and clonality in H. pylori strains.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents, Local; beta-Lactamases; Clarithromycin; | 2009 |
[Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Enzyme-Linked I | 2009 |
Characterization of multiple Helicobacter bizzozeronii isolates from a Finnish patient with severe dyspeptic symptoms and chronic active gastritis.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteriological Techniques; Catalase; Culture Media; DNA, | 2010 |
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Child; Child, Presch | 2010 |
Selective immunoglobulin M deficiency in a patient with refractory giardiasis.
Topics: Adolescent; Antiprotozoal Agents; Diarrhea; Duodenitis; Giardia lamblia; Giardiasis; Humans; Immunog | 2010 |
Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study).
Topics: Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combina | 2010 |
Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Bacterial P | 2012 |
Bismuth subcitrate/metronidazole/ tetracycline--Axcan Pharma. Bismuth triple therapy--Axcan Pharma, Helicide.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Hum | 2002 |
[Association among anti-CagA antibody detection, antibiotic susceptibility, and peptic ulcer in patients with Helicobacter pylori infection].
Topics: Adult; Aged; Antibodies, Bacterial; Antibody Specificity; Antigens, Bacterial; Bacterial Proteins; C | 2003 |
Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases.
Topics: Anti-Bacterial Agents; Asian People; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacte | 2003 |
Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population.
Topics: Asian People; Biopsy; Drug Resistance, Bacterial; Dyspepsia; Ethnicity; Female; Helicobacter Infecti | 2003 |
Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Helic | 2003 |
Helicobacter pylori: a historical perspective 1983-2003.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Drug Therapy, Combination; Esophagitis, Peptic | 2004 |
[Study on metronidazole resistance to Helicobacter pylori from three populations with different ethnics in Yunnan].
Topics: Adult; China; Chronic Disease; Drug Resistance, Bacterial; Female; Gastritis; Helicobacter Infection | 2004 |
[The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years].
Topics: Adult; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Inf | 2005 |
[Prevalence of Helicobacter pylori resistant to clarithromycin, amoxicillin and metronidazole in children].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Drug Resist | 2004 |
Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori.
Topics: Anti-Infective Agents; Bacterial Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Genome, Bacte | 2005 |
Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; He | 2006 |
[Medical, social, and economic effectiveness of treatment of day-case patients with peptic ulcer].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Cost-Benefit An | 2006 |
Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe.
Topics: Adolescent; Age Distribution; Amoxicillin; Anti-Infective Agents; Child; Child, Preschool; Clarithro | 2006 |
Helicobacter pylori antibiotic resistance in a Dutch region: trends over time.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacteria | 2006 |
Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Alleles; Amoxicillin; Anti- | 2006 |
Guidelines in the medical treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Dyspeps | 2006 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dysp | 2007 |
[Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disk Diffusion Antimicrobial Tests; | 2007 |
Small-bowel bacterial overgrowth in the postgastrectomy syndrome.
Topics: Adult; Aged; Bacteria, Aerobic; Bacteria, Anaerobic; Bacteriological Techniques; Breath Tests; Femal | 1983 |
[Metronidazole in the treatment of peptic ulcer].
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Female; Humans; Male; Metronidazole; Middle Aged; Peptic Ul | 1981 |
[Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Dr | 1995 |
90% cure: which anti-Helicobacter therapy can achieve this treatment goal?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 1995 |
Effect of Helicobacter pylori eradication on peptic ulcer healing.
Topics: Adult; Aged; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacte | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; | 1995 |
One-week low-dose triple therapy: new standards for Helicobacter pylori treatment.
Topics: Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; He | 1995 |
Hitting H pylori for four.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; | 1995 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combinatio | 1994 |
[10 days of triple treatment of Helicobacter pylori infection and peptic ulcer. Status after treatment of 4 weeks and of one year].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; | 1994 |
[A Norwegian conference on updating of the treatment of Helicobacter pylori in peptic ulcer. Interessegruppe for Gastroenterologi].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicob | 1994 |
Ribotyping patterns and emergence of metronidazole resistance in paired clinical samples of Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; DNA, Bacterial; DNA, Ribosomal; Drug Resistance, Microbial; Drug The | 1994 |
Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastrins; Gastritis; Helicobacter Infection | 1994 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1994 |
Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing.
Topics: Adult; Bismuth; Female; Food; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; | 1993 |
[Helicobacter pylori infection and peptic ulcer].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 1993 |
One-day therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Administration Schedule; Drug Therapy, | 1993 |
Treatment of peptic ulcers caused by Helicobacter pylori.
Topics: Amoxicillin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metron | 1993 |
Antimicrobial susceptibility pattern & biotyping of Helicobacter pylori isolates from patients with peptic ulcer diseases.
Topics: Adolescent; Adult; Bacterial Typing Techniques; Child; Disease Susceptibility; Drug Resistance, Micr | 1995 |
Evaluation of a new bismuth-free triple therapy in nude mice and humans.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Colony Count, Microbial; C | 1995 |
Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Female; Gastric Mucosa; Ga | 1996 |
Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong.
Topics: Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Case-Control Studies; China; Drug Resistance, Mic | 1996 |
One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; A | 1996 |
An audit of low dose triple therapy for eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Antitrichomonal Agents; Drug Therapy, Combination; Female; Gastr | 1996 |
Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolates from patients with gastritis or peptic ulcer disease.
Topics: Drug Resistance, Microbial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metroni | 1996 |
Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy).
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug | 1996 |
Eradication of helicobacter pylori among patients from a primary care practice.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Endosco | 1996 |
Six months' experience with a pharmacist-run Helicobacter pylori treatment clinic.
Topics: Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Cost of Illness; Drug Therapy, | 1996 |
Drugs for treatment of peptic ulcers.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Drug Inte | 1997 |
A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Dru | 1997 |
[Triple ranitidine therapy in Helicobacter pylori infection. Recommendation for effective, safe and cost effective combination for Helicobacter pylori eradication].
Topics: Amoxicillin; Anti-Ulcer Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Admini | 1996 |
[Helicobacter pylori eradication: finally clarity].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter I | 1996 |
Eradication therapy in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Monitoring; Drug Therapy, Combination; Helicobacter I | 1997 |
Identification and eradication of Helicobacter pylori in an isolated patient population.
Topics: Amoxicillin; Bismuth; Cost Savings; Drug Therapy, Combination; Helicobacter Infections; Helicobacter | 1997 |
Sensitivity of Helicobacter pylori to metronidazole.
Topics: Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Mic | 1997 |
Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedu | 1998 |
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Administ | 1998 |
Helicobacter pylori and peptic ulcer disease therapies: a survey of gastroenterologists in Israel.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Health Care Surveys; Helicobacter pylori; Humans | 1998 |
Eradication of Helicobacter pylori restores elevation of serum gastrin concentrations in patients with end-stage renal disease.
Topics: Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastric Juice; | 1998 |
Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1997 |
Characterization of clinical isolates of Helicobacter pylori in Singapore.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Bacterial Typing Techni | 1998 |
The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicob | 1998 |
One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal | 1998 |
Understanding peptic ulcer disease pharmacotherapeutics.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicob | 1999 |
Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases.
Topics: ABO Blood-Group System; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigens, Bacterial; | 1998 |
Comparative evaluation of two methods for testing metronidazole susceptibility of Helicobacter pylori in routine practice.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Drug Resistance, Microbial; | 1999 |
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Bism | 1999 |
Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 2000 |
A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule.
Topics: Adult; Aged; Anti-Ulcer Agents; Capsules; Female; Gastritis; Gastroscopy; Helicobacter Infections; H | 2000 |
Metronidazole and clarithromycin susceptibility and the subtypes of vacA of Helicobacter pylori isolates in Estonia.
Topics: Adolescent; Adult; Aerobiosis; Aged; Anaerobiosis; Anti-Bacterial Agents; Bacterial Proteins; Clarit | 2000 |
Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bulgaria; Child; Child, Preschool; Chronic Disease; | 2000 |
Metronidazole-resistant Helicobacter pylori in an urban Asian population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Asia; Drug Resistance, Microbial; | 2000 |
[Helicobacter pylori eradication in gastroduodenal ulcer: good, fine and not expensive].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug T | 2000 |
[Upgrading efficiency and safety of combined antihelicobacterial treatment of ulcer patients using modern clinicopharmacological approaches].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Therapy, Com | 2000 |
Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarith | 2000 |
Helicobacter pylori: changing patterns of ulcer disease and antibiotic resistance.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Australia; Clarit | 2000 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
[Current principles of the use of laparoscopic surgery in gastroduodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2001 |
Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bangladesh; Body Mass Index; Breath Tests; Carbon Isotopes; D | 2001 |
Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Clarithromycin; DNA, Bacterial; Dru | 2001 |
Six-year follow-up after successful triple therapy for Helicobacter pylori infection in patients with peptic ulcer disease.
Topics: Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Follow- | 2001 |
The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang.
Topics: Amoxicillin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Area Under Curve; | 2001 |
[Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; D | 2002 |
Metronidazole: avoid it unless it's very much indicated (avoid its routine prescription).
Topics: Anti-Bacterial Agents; Drug Prescriptions; Drug Resistance, Bacterial; Helicobacter Infections; Heli | 2002 |
In vitro anti-Helicobacter pylori activity of BAS-118, a new benzamide derivative.
Topics: Anti-Bacterial Agents; Benzamides; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infectio | 2002 |
[Treatment of peptic ulcer with metronidazole (clinico-experimental study)].
Topics: Adult; Aged; Animals; Drug Evaluation; Female; Humans; Male; Metronidazole; Middle Aged; Peptic Ulce | 1976 |
[New therapeutic developments in gastroenterology].
Topics: Amebiasis; Atropa belladonna; Gastrointestinal Diseases; Metronidazole; Peptic Ulcer; Phytotherapy; | 1975 |
Eradication of Helicobacter pylori reduces gastric and duodenal ulcer recurrence.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compoun | 1992 |
Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Dose-Response | 1992 |
The role of Helicobacter pylori in the pathogenesis of acid-peptic disease.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Black or African American; Dyspepsia; Gastritis; Helicobac | 1992 |
Metronidazole in acid peptic disease.
Topics: Amebiasis; Antacids; Campylobacter Infections; Drug Therapy, Combination; Dyspepsia; Humans; Metroni | 1990 |
[Morphologic change in Campylobacter pylori associated gastritis in and following successful antibacterial therapy].
Topics: Amoxicillin; Bismuth; Campylobacter Infections; Drug Therapy, Combination; Gastric Mucosa; Gastritis | 1989 |